Elbit Imaging Ltd. announced that the first treatment was performed under Phase I clinical trial to investigate the use of Magnetic Resonance Imaging guided by Focused Ultrasound (MRgFUS) technology for opening the blood brain barrier in patients with early Alzheimer's disease. The treatment was conducted at Sunnybrook Health Sciences Centre in Toronto, Canada and use the INSIGHTEC's Exablate Neuro system. INSIGHTEC is the regulatory sponsor of the clinical trial. The purpose of the study is to evaluate the safety and feasibility of low frequency MRgFUS to temporarily open the blood-brain barrier ("BBB") in patients with mild to moderate Alzheimer's disease. This is the first human application of MRgFUS in Alzheimer's patients. The BBB is a protective barrier that restricts the passage of substances from the bloodstream into the brain, protecting it from toxic chemicals. This barrier also prevents the delivery of essential medication to reach the brain.